

Stephanie S O'malley

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3341920/publications.pdf>

Version: 2024-02-01

160
papers

10,218
citations

66343

42
h-index

36028

97
g-index

165
all docs

165
docs citations

165
times ranked

6908
citing authors

#	ARTICLE	IF	CITATIONS
1	Harm reduction for smokers with little to no quit interest: can tobacco policies encourage switching to e-cigarettes?. <i>Tobacco Control</i> , 2023, 32, e173-e179.	3.2	5
2	U.S. Prescribing of On-and-Off-Label Medications for Alcohol Use Disorder in Outpatient Visits: NAMCS 2014 to 2016. <i>Journal of General Internal Medicine</i> , 2022, 37, 495-498.	2.6	3
3	Within- and between-person effects of naltrexone on the subjective response to alcohol and craving: A daily diary investigation. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 477-491.	2.4	4
4	Multimodal neuroimaging of metabotropic glutamate 5 receptors and functional connectivity in alcohol use disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, , .	2.4	0
5	Sensitivity, specificity, and tolerability of the BACTrack <i>Skyn</i> compared to other alcohol monitoring approaches among young adults in a field-based setting. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 783-796.	2.4	8
6	Predictors of abstinence, no heavy drinking days, and a 2-level reduction in World Health Organization drinking levels during treatment for alcohol use disorder in the COMBINE study. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 1331-1339.	2.4	1
7	Differences in the association between kappa opioid receptors and pain among Black and White adults with alcohol use disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 1348-1357.	2.4	2
8	Differences in flavourant levels and synthetic coolant use between USA, EU and Canadian Juul products. <i>Tobacco Control</i> , 2021, 30, 453-455.	3.2	34
9	Occupancy of the kappa opioid receptor by naltrexone predicts reduction in drinking and craving. <i>Molecular Psychiatry</i> , 2021, 26, 5053-5060.	7.9	17
10	The future of translational research on alcohol use disorder. <i>Addiction Biology</i> , 2021, 26, e12903.	2.6	22
11	Quantification of Flavorants and Nicotine in Waterpipe Tobacco and Mainstream Smoke and Comparison to E-cigarette Aerosol. <i>Nicotine and Tobacco Research</i> , 2021, 23, 600-604.	2.6	8
12	Drinking and responses to antidrinking messages among young adults: An fMRI study. <i>Addiction Biology</i> , 2021, 26, e12882.	2.6	2
13	Stability of Drinking Reductions and Long-term Functioning Among Patients with Alcohol Use Disorder. <i>Journal of General Internal Medicine</i> , 2021, 36, 404-412.	2.6	12
14	Multiple Psychiatric Morbidity and Continued Use of Naltrexone for Alcohol Use Disorder. <i>American Journal on Addictions</i> , 2021, 30, 55-64.	1.4	2
15	Adapting Research Protocols in Response to E-Cigarette, or Vaping, Product Use Associated Lung Injury: A Response to CDC Recommendations for E-Cigarette Trials. <i>Nicotine and Tobacco Research</i> , 2021, 23, 619-620.	2.6	0
16	A Multimodal Mobile Sleep Intervention for Young Adults Engaged in Risky Drinking: Protocol for a Randomized Controlled Trial. <i>JMIR Research Protocols</i> , 2021, 10, e26557.	1.0	4
17	73936 Developing a Patient-Rated Outcome Measure of Alcohol and Drug Craving: A Systematic Review. <i>Journal of Clinical and Translational Science</i> , 2021, 5, 39-39.	0.6	0
18	Reward drinking and naltrexone treatment response among young adult heavy drinkers. <i>Addiction</i> , 2021, 116, 2360-2371.	3.3	13

#	ARTICLE	IF	CITATIONS
19	Mapping data-driven individualized neurobehavioral phenotypes in heavy alcohol drinkers. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 841-853.	2.4	3
20	Bringing Together Behavioral Science, Community Engagement, and Cultural Adaptations to Increase Alcohol Abstinence Among American Indian and Alaska Native People Using Contingency Management Therapy. <i>JAMA Psychiatry</i> , 2021, 78, 595.	11.0	2
21	Smartband-Based Automatic Smoking Detection and Real-time Mindfulness Intervention: Protocol for a Feasibility Trial. <i>JMIR Research Protocols</i> , 2021, 10, e32521.	1.0	6
22	Drug and alcohol treatment utilization and barriers among Black, American Indian/Alaskan Native, Latine, Asian/Pacific Islander/Native Hawaiian, and White adults: Findings from NESARC-III. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108569.	2.8	15
23	Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. <i>Neuropsychopharmacology</i> , 2021, 46, 2132-2139.	5.4	19
24	Saracatinib Fails to Reduce Alcohol-Seeking and Consumption in Mice and Human Participants. <i>Frontiers in Psychiatry</i> , 2021, 12, 709559.	2.6	2
25	Characteristics of Registered Clinical Trials Evaluating the Role of e-Cigarettes in Cessation or Reduction of Cigarette Smoking. <i>JAMA Psychiatry</i> , 2021, 78, 1280-1283.	11.0	5
26	Effects of the Fyn kinase inhibitor saracatinib on ventral striatal activity during performance of an fMRI monetary incentive delay task in individuals family history positive or negative for alcohol use disorder. A pilot randomised trial. <i>Neuropsychopharmacology</i> , 2021, , .	5.4	2
27	Use and perceptions of electronic nicotine delivery systems among patients attending lung cancer screening who smoke. <i>Preventive Medicine Reports</i> , 2021, 23, 101444.	1.8	2
28	The effect of varenicline on smoking and drinking outcomes among Black and White adults with alcohol use disorder and co-occurring cigarette smoking: A secondary analysis of two clinical trials. <i>Addictive Behaviors</i> , 2021, 122, 106970.	3.0	3
29	Pilot Ecological Momentary Assessment Study of Subjective and Contextual Factors Surrounding E-Cigarette and Combustible Tobacco Product Use among Young Adults. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11005.	2.6	9
30	Evaluating the effect of switching to non-menthol cigarettes among current menthol smokers: an empirical study of a potential ban of characterising menthol flavour in cigarettes. <i>Tobacco Control</i> , 2020, 29, tobaccocontrol-2019-055154.	3.2	18
31	Models for Analyzing Zero-Inflated and Overdispersed Count Data: An Application to Cigarette and Marijuana Use. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1390-1398.	2.6	39
32	Modulation of "Protective" Nicotine Perception and Use Profile by Flavorants: Preliminary Findings in E-cigarettes. <i>Nicotine and Tobacco Research</i> , 2020, 22, 771-781.	2.6	26
33	Craving to Quit: A Randomized Controlled Trial of Smartphone App-Based Mindfulness Training for Smoking Cessation. <i>Nicotine and Tobacco Research</i> , 2020, 22, 324-331.	2.6	112
34	Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial. <i>Neuropsychopharmacology</i> , 2020, 45, 319-326.	5.4	8
35	The Association of Impulsivity and Family History of Alcohol Use Disorder on Alcohol Use and Consequences. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 159-167.	2.4	17
36	Acute alcohol consumption alters the peripheral cytokines IL-8 and TNF- α . <i>Alcohol</i> , 2020, 85, 95-99.	1.7	18

#	ARTICLE	IF	CITATIONS
37	An integrated behavioural intervention combined with varenicline for heavy-drinking smokers: a randomized pilot study. <i>Journal of Smoking Cessation</i> , 2020, 15, 119-127.	1.0	4
38	Interaction of Ethanol and Oral ANSâ€“6637, a Selective ALDH2 Inhibitor in Males: A Randomized, Doubleâ€“Blind, Placeboâ€“Controlled, Singleâ€“Ascending Dose Cohort Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1885-1895.	2.4	3
39	Examining the Relationship Between Selfâ€“Reported Drinking and Inâ€“Laboratory Drinking and Craving: Is There Concordance?. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1151-1157.	2.4	1
40	Data Visualization Tools of Tobacco Product Use Patterns, Transitions and Sex Differences in the PATH Youth Data. <i>Nicotine and Tobacco Research</i> , 2020, 22, 1901-1908.	2.6	4
41	Effects of Alcohol Cue Reactivity on Subsequent Treatment Outcomes Among Treatmentâ€“Seeking Individuals with Alcohol Use Disorder: A Multisite Randomized, Doubleâ€“Blind, Placeboâ€“Controlled Clinical Trial of Varenicline. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1431-1443.	2.4	23
42	Characteristics of Ongoing Clinical Trials for Alcohol Use Disorder Registered on ClinicalTrials.gov. <i>JAMA Psychiatry</i> , 2020, 77, 1081.	11.0	5
43	Reduction in World Health Organization Risk Drinking Levels and Cardiovascular Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 1625-1635.	2.4	17
44	World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. <i>Addiction</i> , 2020, 115, 1668-1680.	3.3	44
45	Using Web-Based Social Media to Recruit Heavy-Drinking Young Adults for Sleep Intervention: Prospective Observational Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e17449.	4.3	9
46	The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. <i>Biological Psychiatry</i> , 2019, 86, 864-871.	1.3	27
47	Flavorantâ€“Solvent Reaction Products and Menthol in JUUL E-Cigarettes and Aerosol. <i>American Journal of Preventive Medicine</i> , 2019, 57, 425-427.	3.0	39
48	Baseline Craving Strength as a Prognostic Marker of Benefit from Smartphone App-Based Mindfulness Training for Smoking Cessation. <i>Mindfulness</i> , 2019, 10, 2165-2171.	2.8	3
49	Reduction in non-abstinent World Health Organization (WHO) drinking risk levels and drug use disorders: 3-year follow-up results in the US general population. <i>Drug and Alcohol Dependence</i> , 2019, 201, 16-22.	3.2	19
50	Reduction in non-abstinent WHO drinking risk levels and depression/anxiety disorders: 3-year follow-up results in the US general population. <i>Drug and Alcohol Dependence</i> , 2019, 197, 228-235.	3.2	42
51	Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 937-944.	2.4	14
52	Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials. <i>JAMA Psychiatry</i> , 2019, 76, 374.	11.0	77
53	Maintenance of World Health Organization Risk Drinking Level Reductions and Posttreatment Functioning Following a Large Alcohol Use Disorder Clinical Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 979-987.	2.4	41
54	Development and psychometric validation of a novel measure of sensory expectancies associated with E-cigarette use. <i>Addictive Behaviors</i> , 2019, 91, 208-215.	3.0	17

#	ARTICLE	IF	CITATIONS
55	A Pilot Clinical Trial of Smoking Cessation Services Implemented in the Workplace for Service Industry Employees. <i>American Journal of Health Promotion</i> , 2019, 33, 516-524.	1.7	3
56	Psychometric Evaluation of the E-cigarette Dependence Scale. <i>Nicotine and Tobacco Research</i> , 2019, 21, 1556-1564.	2.6	52
57	A Test of Multisession Automatic Action Tendency Retraining to Reduce Alcohol Consumption Among Young Adults in the Context of a Human Laboratory Paradigm. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 803-814.	2.4	16
58	Text Messaging to Reduce Alcohol Relapse in Prelisting Liver Transplant Candidates: A Pilot Feasibility Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 761-769.	2.4	21
59	Longitudinal Associations Between Alcohol-Related Cognitions and Use in African American and European American Adolescent Girls. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 962-971.	2.4	1
60	The Self-Report Habit Index: Assessing habitual marijuana, alcohol, e-cigarette, and cigarette use. <i>Drug and Alcohol Dependence</i> , 2018, 186, 207-214.	3.2	27
61	A fMRI study on the impact of advertising for flavored e-cigarettes on susceptible young adults. <i>Drug and Alcohol Dependence</i> , 2018, 186, 233-241.	3.2	35
62	Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking. <i>JAMA Psychiatry</i> , 2018, 75, 129.	11.0	79
63	Assessing nicotine dependence in adolescent E-cigarette users: The 4-item Patient-Reported Outcomes Measurement Information System (PROMIS) Nicotine Dependence Item Bank for electronic cigarettes. <i>Drug and Alcohol Dependence</i> , 2018, 188, 60-63.	3.2	117
64	Use of Electronic Cigarettes Leads to Significant Beta2-Nicotinic Acetylcholine Receptor Occupancy: Evidence From a PET Imaging Study. <i>Nicotine and Tobacco Research</i> , 2018, 20, 425-433.	2.6	35
65	Mecamylamine treatment for alcohol dependence: a randomized controlled trial. <i>Addiction</i> , 2018, 113, 6-14.	3.3	23
66	Measuring E-cigarette dependence: Initial guidance. <i>Addictive Behaviors</i> , 2018, 79, 213-218.	3.0	41
67	Drinking Risk Level Reductions Associated with Improvements in Physical Health and Quality of Life Among Individuals with Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2453-2465.	2.4	82
68	Reduction in Nonabstinent <sc>WHO</sc> Drinking Risk Levels and Change in Risk for Liver Disease and Positive <sc>AUDIT</sc> Scores: Prospective 3-Year Follow-Up Results in the <sc>U.S.</sc> General Population. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2256-2265.	2.4	43
69	Presence of High-Intensity Sweeteners in Popular Cigarillos of Varying Flavor Profiles. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 1380.	7.4	13
70	Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 2011-2021.	2.4	13
71	Sweet taste potentiates the reinforcing effects of e-cigarettes. <i>European Neuropsychopharmacology</i> , 2018, 28, 1089-1102.	0.7	26
72	Comparing cigarette and e-cigarette dependence and predicting frequency of smoking and e-cigarette use in dual-users of cigarettes and e-cigarettes. <i>Addictive Behaviors</i> , 2018, 87, 92-96.	3.0	31

#	ARTICLE	IF	CITATIONS
73	Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer. <i>Journal of Smoking Cessation</i> , 2018, 13, 244-247.	1.0	5
74	Plasma Menthol Glucuronide as a Biomarker of Acute Menthol Inhalation. <i>Tobacco Regulatory Science (discontinued)</i> , 2018, 4, 586-591.	0.2	8
75	Reciprocal variations in sleep and drinking over time among heavy-drinking young adults.. <i>Journal of Abnormal Psychology</i> , 2018, 127, 92-103.	1.9	29
76	Preferring more e-cigarette flavors is associated with e-cigarette use frequency among adolescents but not adults. <i>PLoS ONE</i> , 2018, 13, e0189015.	2.5	105
77	Temporal Stability of Heavy Drinking Days and Drinking Reductions Among Heavy Drinkers in the <scp>COMBINE</scp> Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1054-1062.	2.4	25
78	A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1201-1211.	2.4	20
79	Letter to Editor in Response to Johnson's Commentary (2017) on the Witkiewitz and Colleagues (2017) Article. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 1381-1382.	2.4	5
80	Change in non-abstinent WHO drinking risk levels and alcohol dependence: a 3 year follow-up study in the US general population. <i>Lancet Psychiatry</i> , 2017, 4, 469-476.	7.4	108
81	Clinical Validation of Reduced Alcohol Consumption After Treatment for Alcohol Dependence Using the World Health Organization Risk Drinking Levels. <i>Alcoholism: Clinical and Experimental Research</i> , 2017, 41, 179-186.	2.4	123
82	Relationships of Impulsivity and Subjective Response to Alcohol Use and Related Problems. <i>Journal of Studies on Alcohol and Drugs</i> , 2017, 78, 835-843.	1.0	14
83	The effect of sucralose on flavor sweetness in electronic cigarettes varies between delivery devices. <i>PLoS ONE</i> , 2017, 12, e0185334.	2.5	20
84	NMDA Glutamate Receptor Antagonism and the Heritable Risk for Alcoholism: New Insights from a Study of Nitrous Oxide. <i>International Journal of Neuropsychopharmacology</i> , 2017, 20, 351-353.	2.1	2
85	Missing Data in Alcohol Clinical Trials with Binary Outcomes. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1548-1557.	2.4	25
86	Nicotine and Nicotine Abstinence Do Not Interfere with GABA_A Receptor Neuroadaptations During Alcohol Abstinence. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 698-705.	2.4	5
87	Brief Report: A web-based pilot study of childhood sexual abuse, recent stressful events, and alcohol use in women. <i>American Journal on Addictions</i> , 2016, 25, 184-187.	1.4	5
88	Meeting the Growing Need for Heroin Addiction Treatment. <i>JAMA Psychiatry</i> , 2016, 73, 437.	11.0	19
89	Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist <scp>LY</scp>2940094 as a New Treatment for Alcohol Dependence. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1935-1944.	2.4	34
90	Fatty acid amide supplementation decreases impulsivity in young adult heavy drinkers. <i>Physiology and Behavior</i> , 2016, 155, 131-140.	2.1	10

#	ARTICLE	IF	CITATIONS
91	Longitudinal findings from a randomized clinical trial of naltrexone for young adult heavy drinkers.. Journal of Consulting and Clinical Psychology, 2016, 84, 185-190.	2.0	10
92	Randomized controlled trial of a very brief, multicomponent web-based alcohol intervention for undergraduates with a focus on protective behavioral strategies.. Journal of Consulting and Clinical Psychology, 2016, 84, 1008-1015.	2.0	25
93	Exploring the Utility of Web-Based Social Media Advertising to Recruit Adult Heavy-Drinking Smokers for Treatment. Journal of Medical Internet Research, 2016, 18, e107.	4.3	24
94	A modified classification tree method for personalized medicine decisions. Statistics and Its Interface, 2016, 9, 239-253.	0.3	9
95	Integrating acquired preparedness and dual process models of risk for heavy drinking and related problems.. Psychology of Addictive Behaviors, 2015, 29, 864-874.	2.1	21
96	Predictors of Abstinence From Heavy Drinking During Follow-Up in COMBINE. Journal of Studies on Alcohol and Drugs, 2015, 76, 935-941.	1.0	15
97	How Imaging Glutamate, γ -Aminobutyric Acid, and Dopamine Can Inform the Clinical Treatment of Alcohol Dependence and Withdrawal. Alcoholism: Clinical and Experimental Research, 2015, 39, 2268-2282.	2.4	21
98	Interactive and Indirect Effects of Anxiety and Negative Urgency on Alcohol-Related Problems. Alcoholism: Clinical and Experimental Research, 2015, 39, 1267-1274.	2.4	11
99	Reduction of Alcohol Drinking in Young Adults by Naltrexone. Journal of Clinical Psychiatry, 2015, 76, e207-e213.	2.2	67
100	Acute alcohol consumption elevates serum bilirubin: An endogenous antioxidant. Drug and Alcohol Dependence, 2015, 149, 87-92.	3.2	14
101	An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. European Neuropsychopharmacology, 2015, 25, 1586-1599.	0.7	11
102	Successful Tobacco Dependence Treatment in Low-Income Emergency Department Patients: A Randomized Trial. Annals of Emergency Medicine, 2015, 66, 140-147.	0.6	50
103	Novel Approaches to Individual Alcohol Interventions for Heavy Drinking College Students and Young Adults. Current Addiction Reports, 2015, 2, 47-57.	3.4	14
104	A randomized controlled trial of smartphone-based mindfulness training for smoking cessation: a study protocol. BMC Psychiatry, 2015, 15, 83.	2.6	67
105	The Yale Craving Scale: Development and psychometric properties. Drug and Alcohol Dependence, 2015, 154, 158-166.	3.2	11
106	Smoking Use and Cessation Among People with Serious Mental Illness. Yale Journal of Biology and Medicine, 2015, 88, 271-7.	0.2	29
107	Psychometrically improved, abbreviated versions of three classic measures of impulsivity and self-control.. Psychological Assessment, 2014, 26, 1003-1020.	1.5	132
108	Tobacco smoking interferes with GABA _A receptor neuroadaptations during prolonged alcohol withdrawal. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 18031-18036.	7.1	21

#	ARTICLE	IF	CITATIONS
109	Predictors of Abstinence from Heavy Drinking During Treatment in <scp>COMBINE</scp> and External Validation in <scp>PREDICT</scp>. Alcoholism: Clinical and Experimental Research, 2014, 38, 2647-2656.	2.4	18
110	Menthol Cigarette Use Predicts Treatment Outcomes of Weight-Concerned Smokers. Nicotine and Tobacco Research, 2014, 16, 115-119.	2.6	11
111	Financial versus health motivation to quit smoking: A randomized field study. Preventive Medicine, 2014, 59, 1-4.	3.4	16
112	Relationships between impulsivity and subjective response in an IV ethanol paradigm. Psychopharmacology, 2014, 231, 2867-2876.	3.1	29
113	Smoking Cessation Is Followed by Increases in Serum Bilirubin, an Endogenous Antioxidant Associated With Lower Risk of Lung Cancer and Cardiovascular Disease. Nicotine and Tobacco Research, 2014, 16, 1145-1149.	2.6	28
114	Predictors of Pretreatment Commitment to Abstinence: Results from the COMBINE Study. Journal of Studies on Alcohol and Drugs, 2014, 75, 438-446.	1.0	33
115	A new look at risk-taking: Using a translational approach to examine risk-taking behavior on the balloon analogue risk task.. Experimental and Clinical Psychopharmacology, 2014, 22, 444-452.	1.8	19
116	The drug effects questionnaire: psychometric support across three drug types. Psychopharmacology, 2013, 227, 177-192.	3.1	165
117	The effects of drinking goal on treatment outcome for alcoholism.. Journal of Consulting and Clinical Psychology, 2013, 81, 13-22.	2.0	60
118	Co-occurring marijuana use is associated with medication nonadherence and nonplanning impulsivity in young adult heavy drinkers. Addictive Behaviors, 2012, 37, 420-426.	3.0	20
119	Cigarette Smoking Predicts Differential Benefit from Naltrexone for Alcohol Dependence. Biological Psychiatry, 2012, 72, 832-838.	1.3	56
120	Varenicline and the Evaluation of Neuropsychiatric Adverse Events in Smokers. Biological Psychiatry, 2011, 69, 1017-1018.	1.3	2
121	A preliminary investigation of varenicline for heavy drinking smokers. Psychopharmacology, 2011, 215, 655-663.	3.1	112
122	Medications for unhealthy alcohol use: across the spectrum. Alcohol Research, 2011, 33, 300-12.	1.0	12
123	Nicotine and food deprivation decrease the ability to resist smoking. Psychopharmacology, 2010, 212, 25-32.	3.1	65
124	Gender Differences in Alcohol Treatment: An Analysis of Outcome From the COMBINE Study. Alcoholism: Clinical and Experimental Research, 2010, 34, 1803-1812.	2.4	85
125	REVIEW: Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes. Addiction Biology, 2010, 15, 109-124.	2.6	116
126	Varenicline Reduces Alcohol Self-Administration in Heavy-Drinking Smokers. Biological Psychiatry, 2009, 66, 185-190.	1.3	275

#	ARTICLE	IF	CITATIONS
127	Dose-dependent reduction of hazardous alcohol use in a placebo-controlled trial of naltrexone for smoking cessation. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 589.	2.1	41
128	Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration. <i>Psychopharmacology</i> , 2008, 196, 189-200.	3.1	66
129	Naltrexone Alone and With Sertraline for the Treatment of Alcohol Dependence in Alaska Natives and Non-Natives Residing in Rural Settings: A Randomized Controlled Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2008, 32, 1271-1283.	2.4	86
130	A pilot study of naltrexone and BASICS for heavy drinking young adults. <i>Addictive Behaviors</i> , 2008, 33, 1048-1054.	3.0	17
131	Risk factors for treatment failure in smokers: Relationship to alcohol use and to lifetime history of an alcohol use disorder. <i>Nicotine and Tobacco Research</i> , 2008, 10, 1793-1809.	2.6	83
132	Smoking Status as a Clinical Indicator for Alcohol Misuse in US Adults. <i>Archives of Internal Medicine</i> , 2007, 167, 716.	3.8	162
133	Efficacy of Extended-Release Naltrexone in Alcohol-Dependent Patients Who Are Abstinent Before Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 507-512.	1.4	108
134	Family History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking. <i>Biological Psychiatry</i> , 2007, 62, 694-697.	1.3	105
135	Naltrexone and Cognitive Behavioral Coping Skills Therapy for the Treatment of Alcohol Drinking and Eating Disorder Features in Alcohol-Dependent Women: A Randomized Controlled Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2007, 31, 070227012339006-???	2.4	65
136	Timing and Predictors of Postpartum Return to Smoking in a Group of Inner-City Women: An Exploratory Pilot Study. <i>Birth</i> , 2007, 34, 245-252.	2.2	30
137	Characteristics of Older Adult Problem Gamblers Calling a Gambling Helpline. <i>Journal of Gambling Studies</i> , 2006, 22, 241-254.	1.6	51
138	Modeling the effect of alcohol on smoking lapse behavior. <i>Psychopharmacology</i> , 2006, 189, 201-210.	3.1	131
139	A Controlled Trial of Naltrexone Augmentation of Nicotine Replacement Therapy for Smoking Cessation. <i>Archives of Internal Medicine</i> , 2006, 166, 667.	3.8	102
140	Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence. <i>JAMA - Journal of the American Medical Association</i> , 2006, 295, 2003.	7.4	1,680
141	How pilot studies improve large-scale clinical trials: lessons learned from the COMBINE Study.. <i>Journal of Studies on Alcohol Supplement</i> , 2005, , 66-71.	0.9	3
142	Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence. <i>JAMA - Journal of the American Medical Association</i> , 2005, 293, 1617.	7.4	545
143	Initial and Maintenance Naltrexone Treatment for Alcohol Dependence Using Primary Care vs Specialty Care. <i>Archives of Internal Medicine</i> , 2003, 163, 1695.	3.8	134
144	Advances in the use of naltrexone: an integration of preclinical and clinical findings. <i>Recent Developments in Alcoholism: an Official Publication of the American Medical Society on Alcoholism, and the Research Society on Alcoholism, and the National Council on Alcoholism</i> , 2003, 16, 217-45.	0.4	34

#	ARTICLE	IF	CITATIONS
145	Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. <i>Psychopharmacology</i> , 2002, 160, 19-29.	3.1	484
146	The Effect of Tryptophan Depletion on Alcohol Self-Administration in Non-Treatment-Seeking Alcoholic Individuals. <i>Alcoholism: Clinical and Experimental Research</i> , 2002, 26, 969-975.	2.4	22
147	Sex differences in [¹²³ I]β-CIT SPECT measures of dopamine and serotonin transporter availability in healthy smokers and nonsmokers. <i>Synapse</i> , 2001, 41, 275-284.	1.2	232
148	Cue-dose training with monetary reinforcement. <i>Journal of General Internal Medicine</i> , 2000, 15, 841-847.	2.6	200
149	Alcohol and Eating Disorders: Implications for Alcohol Treatment and Health Services Research. <i>Alcoholism: Clinical and Experimental Research</i> , 2000, 24, 1312-1319.	2.4	61
150	Alcohol and Eating Disorders: Implications for Alcohol Treatment and Health Services Research. <i>Alcoholism: Clinical and Experimental Research</i> , 2000, 24, 1312-1319.	2.4	1
151	Association of Alcohol or Other Drug Dependence with Alleles of the mu Opioid Receptor Gene (OPRM1). <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 1359-1362.	2.4	48
152	Treatment of Early AIDS Dementia in Intravenous Drug Users: High Versus Low Dose Peptide T. <i>American Journal of Drug and Alcohol Abuse</i> , 1997, 23, 543-553.	2.1	12
153	Addiction Severity and MMPI-Derived Typologies in Cocaine Abusers. <i>American Journal on Addictions</i> , 1997, 6, 83-86.	1.4	5
154	Eating Pathology among Women with Alcoholism and/ or Anxiety Disorders. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 1184-1191.	2.4	24
155	Psychotherapeutic Considerations in Pharmacological Trials. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 17A-22A.	2.4	39
156	Six-Month Follow-up of Naltrexone and Psychotherapy for Alcohol Dependence. <i>Archives of General Psychiatry</i> , 1996, 53, 217.	12.3	240
157	Pharmacologic Interventions for Alcohol- and Cocaine-Abusing Individuals. <i>American Journal on Addictions</i> , 1993, 2, 77-79.	1.4	5
158	Naltrexone and Coping Skills Therapy for Alcohol Dependence. <i>Archives of General Psychiatry</i> , 1992, 49, 881.	12.3	1,409
159	Neuropsychological Impairment in Chronic Cocaine Abusers. <i>American Journal of Drug and Alcohol Abuse</i> , 1992, 18, 131-144.	2.1	256
160	Dual diagnoses: Substance abuse and personality disorders. <i>New Directions for Mental Health Services</i> , 1990, 1990, 115-137.	0.4	8